MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung ...

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some ...

Fibroblastic reticular cells (FRCs) create T-cell-supportive niches within lung cancer tumors, facilitating T-cell migration, ...

Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...

When Ed O. went to the ER for shortness of breath and trembling, he never imagined he’d receive a diagnosis of unresectable ...

Institute of Immunobiology-led research has made a significant breakthrough in understanding how the body combats lung cancer ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about ...

At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus ...

A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...